Stryker Corporation (NYSE:SYK) Shares Acquired by Natixis Advisors LLC

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Natixis Advisors LLC boosted its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 191,989 shares of the medical technology company's stock after purchasing an additional 7,172 shares during the quarter. Natixis Advisors LLC owned about 0.05% of Stryker worth $71,468,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of SYK. NorthRock Partners LLC boosted its position in shares of Stryker by 2.0% in the 1st quarter. NorthRock Partners LLC now owns 15,945 shares of the medical technology company's stock worth $5,936,000 after purchasing an additional 320 shares in the last quarter. Baader Bank Aktiengesellschaft boosted its position in shares of Stryker by 376.8% in the 1st quarter. Baader Bank Aktiengesellschaft now owns 24,243 shares of the medical technology company's stock worth $9,016,000 after purchasing an additional 19,158 shares in the last quarter. Woodley Farra Manion Portfolio Management Inc. boosted its position in shares of Stryker by 2.3% in the 1st quarter. Woodley Farra Manion Portfolio Management Inc. now owns 144,176 shares of the medical technology company's stock worth $53,786,000 after purchasing an additional 3,259 shares in the last quarter. Arkadios Wealth Advisors boosted its position in shares of Stryker by 495.9% in the 1st quarter. Arkadios Wealth Advisors now owns 4,052 shares of the medical technology company's stock worth $1,508,000 after purchasing an additional 3,372 shares in the last quarter. Finally, First National Trust Co lifted its position in Stryker by 2.1% during the 1st quarter. First National Trust Co now owns 18,561 shares of the medical technology company's stock worth $6,909,000 after acquiring an additional 374 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Sanford C. Bernstein set a $450.00 price objective on Stryker in a research note on Monday, May 5th. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday. Wells Fargo & Company lifted their price target on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research note on Friday. Finally, BTIG Research restated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and a consensus target price of $429.35.

Stryker Stock Down 3.6%

Shares of Stryker stock traded down $14.11 during trading hours on Friday, reaching $378.62. 3,012,250 shares of the company were exchanged, compared to its average volume of 1,156,084. Stryker Corporation has a 1 year low of $314.93 and a 1 year high of $406.19. The stock's fifty day moving average is $387.46 and its 200 day moving average is $380.30. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The firm has a market cap of $144.52 billion, a PE ratio of 50.15, a PEG ratio of 2.91 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 24.12% and a net margin of 12.25%. The company's revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.81 earnings per share. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Monday, June 30th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Monday, June 30th. Stryker's dividend payout ratio is 45.41%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director owned 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.